J0567 Injection., cerliponase alfa 1 milligrams
Also known as: cerliponase alfa, Brineura
Cerliponase alfa injection, 1 milligram, an enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2) delivered intracerebrally.
In Plain Language
brain enzyme replacement for rare childhood disease; CLN2 treatment
Clinical Context
Specifically indicated for late-infantile neuronal ceroid lipofuscinosis type 2, a rare inherited lysosomal storage disorder causing progressive neurodegeneration. Administered directly into cerebrospinal fluid via intracerebroventricular catheter.
RVU Information
CPT J0567 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0567?
CPT J0567 (Injection., cerliponase alfa 1 milligrams) is a J Codes (Drugs) code. Cerliponase alfa injection, 1 milligram, an enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2) delivered intracerebrally.
How is J0567 administered?
CPT J0567 is administered by a healthcare provider, typically via injection or infusion. Specifically indicated for late-infantile neuronal ceroid lipofuscinosis type 2, a rare inherited lysosomal storage disorder causing progressive neurodegeneration. Administered directly into cerebrospinal fluid via intracerebroventricular catheter. It is used by pediatric neurology, genetic medicine, neurosurgery.
When is CPT J0567 used?
Specifically indicated for late-infantile neuronal ceroid lipofuscinosis type 2, a rare inherited lysosomal storage disorder causing progressive neurodegeneration. Administered directly into cerebrospinal fluid via intracerebroventricular catheter.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.